DOJ joins lawsuits alleging Kaiser Permanente committed Medicare fraud
Attempts to “defraud the program cannot continue and will be pursued,” DOJ officials said in statement announcing the action against the California-based system.
For-profit hospitals saw volumes rebound in Q2, but delta variant poses threat
Some services were near or back to pre-pandemic levels in the second quarter, though others like ER visits are still lagging. At the same time, increasing cases of the delta variant could hinder full recoveries this year.
Despite pandemic, independent medical practices say they are more confident than ever
This feeling of optimism came despite the fact that 11% of independent medical practices said they had shut down temporarily during the COVID-19 crisis, according to a new survey.
Patient deaths called ‘injury,’ ‘other’ in FDA medical device database: study
Mislabeled patient death reports can go missed by FDA, potentially leading to unsafe devices remaining on the market, a researcher noted. The analysis raises questions about the complex and often opaque reporting system.
A deep dive into the former GSA EPLS, SAM.gov
Have burning questions about the SAM.gov database? Don’t worry; we’ve got you covered! Read on for an overview of one of the main primary sources: SAM.gov.
Telehealth investments soar even as market matures
In the second quarter, late-stage investments outpaced those going into early-stage deals. Moreover, investor exits also reached a record high, according to CB Insights.
Cerner reports $1.5B in revenue, raises full-year guidance
Net income, however, plummeted in the second quarter as restructuring charges dragged on the health IT giant’s margin.
Telehealth investments soar even as market is maturing
In the second quarter late-stage investments outpaced those going into early-stage deals. Moreover, investor exits also reached a record high, according to CB Insights.
AstraZeneca still eyes US vaccine filing despite another delay
The company now expects to file for full approval by year’s end and has a variant-specific shot in advanced testing. But the long-term prospects for AstraZeneca’s new vaccine business are unclear.
‘Pent up demand’ spurs Centene Q2 net loss as more members seek care
Executives warned, however, that the delta variant is raging. “It remains clear that the pandemic is not over, and the environment could remain choppy for the balance of the year,” CEO Michael Neidorff said.